Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can
A phase 2 trial of Botensilimab in colorectal cancer, run by Stingray Therapeutics, now recruiting.
Overview
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) is a phase 2 interventional study registered as NCT06589440 by Stingray Therapeutics, with 70 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-07-31. Interventions recorded: SR-8541A. Conditions listed: Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC). No results are recorded here; the registry entry is the source.
Setting
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Phase
Phase 2
Sponsor
Stingray Therapeutics
Registry
Enrolled
70